Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | YARS1 | P54577 | 2/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11799017 | 1.00 | ACE (0.55) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL9822681 | 1.00 | ACE (0.55) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL30974364 | 0.95 | CTSD (0.54) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL30714767 | 0.95 | OPRD1 (0.53) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL29822653 | 0.94 | ACE (0.59) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL29804710 | 0.92 | ACE (0.54) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL31193449 | 0.92 | OPRD1 (0.52) | ACEMMECPA1ACE2SLC7A5 | |
| SCHEMBL30272520 | 0.91 | OPRD1 (0.58) | ACEMMECPA1ACE2OPRD1 | |
| SCHEMBL30714772 | 0.90 | OPRD1 (0.49) | ACEMMECPA1ACE2YARS1 | |
| SCHEMBL3052108 | 0.89 | CTSD (0.57) | ACEMMECPA1ACE2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4622992-A1 | COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY | Amyndas Pharmaceuticals US LLC (US) | 2025-10-01 | — | — | EP | claimed |
| CN-119955884-A | Oat polypeptide extracted by directional enzyme digestion and method and application thereof | 杭州恩和生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119639852-A | Preparation process and application of small fruit coffee grounds derived polypeptides | 杭州恩和生物科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024110878-A1 | COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY | AMYNDAS PHARMACEUTICALS US LLC (US) | 2024-05-30 | — | — | WO | claimed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116350746-A | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| CN-115996942-A | Macrophage-targeting peptides, conjugates, compositions and uses thereof | 双亥生命科学株式会社 | 2023-04-21 | — | — | CN | claimed |
| CN-115397836-A | Novel antibacterial peptide and application thereof | 安尼根有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| CN-104788537-B | A kind of tetrapeptides compound and its preparation method and application | 中国科学院长春应用化学研究所 | 2018-03-13 | — | — | CN | claimed |
| CN-104788537-A | Novel tetrapeptide compound as well as preparation method and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2015-07-22 | — | — | CN | claimed |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | ACTICOR BIOTECH (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-3975365-A | Inhibitory octapeptides angiotensin II | G. D. SEARLE & CO. (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | SSB, IGSF11, CD22 | ACE 4384/4885MME 3398/4885CPA1 759/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885MME 824/4885CPA1 245/4885 |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | IGLV6-57, GP6, VSIG8 | ACE 4465/4885MME 4088/4885CPA1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.